<DOC>
	<DOCNO>NCT00485589</DOCNO>
	<brief_summary>This study evaluate efficacy safety ocrelizumab , compare placebo , combination methotrexate patient active rheumatoid arthritis naive methotrexate . Patients randomize receive placebo , ocrelizumab 200mg i.v . ocrelizumab 500mg i.v . Days 1 15 . Repeat course i.v . treatment administer week 24 , 52 76 . All patient receive concomitant methotrexate ( 7.5 mg escalate 20mg p.o . weekly ) . The anticipated time study treatment 2+ year , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Ocrelizumab Combination With Methotrexate Patients With Rheumatoid Arthritis Who Are Naive Methotrexate ( FILM )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Inclusion criterion : Age â‰¥ 18 Rheumatoid arthritis 3 months5 year Naive methotrexate If receiving steroid NSAIDs , must stable dose 4 week prior baseline Exclusion criterion : Rheumatic autoimmune disease inflammatory joint disease RA Prior receipt biologic therapy RA Concurrent treatment DMARD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>FILM</keyword>
	<keyword>RA</keyword>
	<keyword>anti-CD20</keyword>
	<keyword>CD20</keyword>
</DOC>